Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, with news flow that reflects activity across its Affordable Medicines, Specialty, and AvKARE segments. This page aggregates company-specific coverage so readers can follow how Amneal’s development, manufacturing, and distribution efforts translate into regulatory milestones, clinical results, and financial performance.
News about Amneal frequently centers on U.S. FDA approvals and regulatory updates. Recent announcements include approvals for denosumab biosimilars referencing Prolia and XGEVA, epinephrine injection in single- and multi-dose vials for hospitals, iohexol injection as a first generic version of Omnipaque, albuterol sulfate inhalation aerosol as a generic equivalent of PROAIR HFA, and cyclosporine ophthalmic emulsion 0.05% as a generic equivalent of RESTASIS. These items illustrate the company’s focus on complex injectables, biosimilars, respiratory therapies, and ophthalmic products within its Affordable Medicines segment.
In the Specialty segment, news coverage highlights branded CNS and endocrine therapies, particularly CREXONT for Parkinson’s disease. Amneal has reported positive interim Phase 4 ELEVATE-PD results and emphasizes CREXONT’s role in improving motor symptom control and "Good On" time. The company also reports on collaborations, such as a research collaboration and option agreement with KeifeRx to advance KFRX06, a brain-penetrant LRRK2 program for Parkinson’s disease.
Investors and analysts will also find financial results and capital markets updates, including quarterly earnings releases, guidance updates, and details of term loan and senior secured notes financings. Governance and corporate events, such as participation in healthcare investor conferences and board changes, are disclosed through press releases and Form 8-K filings.
For users tracking AMRX, this news feed provides a centralized view of regulatory decisions, product launches, clinical data, financing transactions, and strategic collaborations that shape Amneal’s business across its three segments.
Amneal Pharmaceuticals (NYSE: AMRX), based in Bridgewater, NJ, is a fully-integrated pharmaceutical company engaged in developing, manufacturing, and distributing generic and specialty drugs. With a portfolio of around 250 product families, the company also focuses on complex dosage forms and branded products in central nervous system and endocrine disorders. Owning 65% of AvKARE, Amneal primarily serves governmental agencies, including the Department of Defense and Veterans Affairs. The company is expanding its reach across North America, Asia, and Europe to deliver high-quality medicines.
Amneal Pharmaceuticals (NYSE: AMRX) and PL Developments have begun shipping store brand equivalent Voltaren® Arthritis Pain Gel (diclofenac sodium topical gel, 1%) in various sizes after receiving FDA clearance. This product, previously available only by prescription, is significant for US consumers. The original Voltaren® Arthritis Pain generated approximately $250 million in sales prior to its switch to OTC in February 2020. This collaboration aims to enhance the availability of affordable generic medicines, demonstrating Amneal's commitment to accessible healthcare.